

11-04-05 ✓

IFW

CASE LI/G-33039A



EV5246/3704 US

11/3/2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

ANTONCIC ET AL.

INTERNATIONAL APPLICATION NO: PCT/SI2004/000001

FILED: 29 JANUARY 2004 ✓

U.S. APPLICATION NO: 10/524,993

35 USC §371 DATE: 18 FEBRUARY 2005

FOR: PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT
OF LOSARTAN AND FORMS THEREOF WITH NEW
PURIFICATION AND ISOLATION METHODS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the "Foreign Applications". The filing date for the fifth foreign application was listed incorrectly. Please issue a corrected filing receipt listing the foreign application area as follows:

--Foreign Applications

SLOVENIA P-200300026 01/30/2003
SLOVENIA P-200300025 01/30/2003
SLOVENIA P-200300145 06/12/2003
SLOVENIA P-200300157 06/26/2003
SLOVENIA P-200300270 11/5/2003 --.

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945
JDT/dd
Encl.: copy of filing receipt
Date:

NOV - 3 2005


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 August 2004 (12.08.2004)

PCT

(10) International Publication Number
WO 2004/066997 A2

(51) International Patent Classification⁷: **A61K 31/4178**,
A61P 9/12, **C07D 403/10**

Franca Fakina 7, 1420 Trbovlje (SI). **MAROLT**, Boris
[SI/SI]; Presemova 7, 1236 Trzin (SI).

(21) International Application Number:
PCT/SI2004/000001

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 29 January 2004 (29.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-200300026 30 January 2003 (30.01.2003) SI
P-200300025 30 January 2003 (30.01.2003) SI
P-200300145 12 June 2003 (12.06.2003) SI
P-200300157 26 June 2003 (26.06.2003) SI
P-200300270 5 November 2003 (05.11.2003) SI

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **LEK
PHARMACEUTICALS D.D.** [SI/SI]; Verovskova 57,
1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANTONCIC**,
Ljubomir [SI/SI]; Podmiljsakova 43, Ljubljana (SI).
COPAR, Anton [SI/SI]; Staretovej trg 1, 1275 Smartno pri
Litiji (SI). **SVETE**, Peter [SI/SI]; Gradisnikova 14, 1353
Borovnica (SI). **HUSU-KOVACECIC**, Breda [SI/SI]; Na
Peci 27, 1000 Ljubljana (SI). **HAM**, Zoran [SI/SI]; Trg

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PREPARATION OF NEW PHARMACEUTICALLY SUITABLE SALT OF LOSARTAN AND FORMS THEREOF
WITH NEW PURIFICATION AND ISOLATION METHODS

(57) Abstract: Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-h idrox-
ymethyl-1-[[2'-(1 H-tetrazole-5-yl)][1.1'-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and
isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline
potassium salts of 2-n-butyl-4-chloro-5hidroxymethyl-1-[[2'-(1 H-tetrazole-5-yl)][1.1'-biphenyl]-4-yl]-1 H-imidazole have been pre-
pared.

WO 2004/066997 A2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/524,993	02/18/2005	1626	2650	LI/G-33039A	32	22	10

CONFIRMATION NO. 3941

FILING RECEIPT



OC000000016974663

1095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080


JDT

Date Mailed: 09/21/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ljubomir Antoncic, Ljubljana, SLOVENIA;
Anton Copar, Smartno pri Litiji, SLOVENIA;
Peter Svete, Borovnica, SLOVENIA;
Breda Husu-Kovacevic, Ljubljana, SLOVENIA;
Zoran Ham, Trbovlje, SLOVENIA;
Boris Marolt, Trzin, SLOVENIA;



Power of Attorney: The patent practitioners associated with Customer Number **1095**.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/SI04/00001 01/29/2004

Foreign Applications

SLOVENIA P-200300026 01/30/2003
SLOVENIA P-200300025 01/30/2003
SLOVENIA P-200300145 06/12/2003
SLOVENIA P-200300157 06/26/2003
SLOVENIA P-200300270 06/26/2003

11/5/2003

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

BEST AVAILABLE COPY

Early Publication Request: No

Title

Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods

Preliminary Class

548

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process ~~simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in~~ countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

BEST AVAILABLE COPY

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).